ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Gene Therapy

NIH, Gates launch $200 million project for HIV and sickle cell disease gene therapy

by Ryan Cross
November 2, 2019 | APPEARED IN VOLUME 97, ISSUE 43

The National Institutes of Health and the Bill & Melinda Gates Foundation are committing $100 million each to develop affordable gene therapies for HIV and sickle cell disease. Sickle cell could be cured with gene-replacement or gene-editing approaches, and preclinical research indicates that CRISPR gene editing could chop up HIV genomes hiding in the body. Both programs will focus on in vivo therapies, in which cells are altered inside the body. The biggest challenge for both could be lowering manufacturing costs.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment